Limitless possibilities are hidden within the DNA that makes up our world. We are at the dawn of an era of technological advances that allow us to discover new proteins and understand their impact on human health and sustainability at an unprecedented rate.
Our core mission at Arbor is to harness this potential by building a biodiscovery platform of unparalleled power, including a comprehensive set of technologies and techniques, such as machine learning, genome sequencing, gene synthesis and high-throughput screening. The diverse backgrounds of our team enables us to tackle challenging obstacles, develop new methods, and advance science for the betterment of humankind.
We are passionate about our work,
because discovery is in our DNA.
David works at the intersection of computer science and biology, leveraging emerging data streams to create exciting new biotechnologies. Prior to co-founding Arbor, David completed his PhD in the laboratory of Feng Zhang at MIT and the Broad Institute, where he contributed to the early development of CRISPR-Cas systems for mammalian genome editing applications. As part of this work, David created experimental and computational techniques to enhance the precision of CRISPR-Cas applications and discover novel CRISPR gene editing systems. David is the recipient of the National Science Foundation Graduate Research Fellowship, the Henry E. Singleton Fellowship, and the Angus MacDonald Award for Excellence in Undergraduate Teaching. He received his BS in Cognitive Science from the University of California San Diego, where he co-authored several research studies illuminating the early progression of Alzheimer’s and Parkinson’s diseases.
Winston is a biotechnologist discovering and developing applications for novel molecular technologies. Prior to co-founding Arbor, Winston worked in the laboratory of Feng Zhang at MIT and the Broad Institute, where he focused on addressing challenges that limit the in vivo therapeutic applications of CRISPR-Cas nucleases. This included developing smaller orthologs of Cas9 for better packaging into the most therapeutically promising viral vectors for gene therapy, building assays that enhance off-target detection to evaluate the genomic safety of CRISPR-Cas enzymes, and additionally searching for new enzyme systems to power genome engineering capabilities beyond nucleases. Winston graduated magna cum laude with a BS in Physics from Harvard College, and PhD in Biophysics from Harvard University as a part of the Harvard-MIT MD/PhD program. Recognition for his research and entrepreneurship has included the Sir Peter Mansfield Research Fellowship, Herchel Smith Undergraduate Research Fellowship, Olken Brothers’ Award for Entrepreneurial Spirit, Harvard I3 Innovation Challenge Winner, Micron Science & Technology Scholarship Top Awardee, and the Paul & Daisy Soros Fellowship.
Feng Zhang is a core institute member of the Broad Institute of MIT and Harvard, as well as an investigator at the McGovern Institute for Brain Research at MIT, the James and Patricia Poitras Professor in Neuroscience at MIT. Feng is a bioengineer developing and applying novel molecular technologies for studying the molecular and genetic basis of diseases and providing treatment. He played a seminal role in developing optogenetics, a powerful technology for dissecting neural circuits using light. Since joining the Broad and McGovern institutes in January 2011, Feng has pioneered the development of genome editing tools for use in eukaryotic cells - including human cells - from natural microbial CRISPR systems. Feng is a recipient of many awards including the Perl/UNC Prize in Neuroscience, the NIH Director's Pioneer Award, the National Science Foundation's Alan T. Waterman Award, the Jacob Heskel Gabbay Award in Biotechnology and Medicine, the Society for Neuroscience Young Investigator Award, the Canada Gairdner International Award, and the Tang Prize. He has also received technology innovation awards from the McKnight, New York Stem Cell, and Damon Runyon foundations. Feng received his AB in Chemistry and Physics from Harvard College and his PhD in Chemistry from Stanford University.
David is Professor in the Department of Pathology, Brigham and Women’s Hospital and Wyss Institute for Biologically Inspired Engineering, and is a Howard Hughes Medical Institute Professor. David is the Scientific Founder of Illumina Inc. and Quanterix Corp and has co-founded several other life sciences startups. David has published over 300 peer-reviewed papers and has over 75 issued US patents. He has received numerous national and international awards and honors for his fundamental and applied work in the field of optical microwell arrays and single molecules including the American Chemical Society Kathryn C. Hach Award for Entrepreneurial Success, Ralph Adams Award in Bioanalytical Chemistry, the American Chemical Society Gustavus John Esselen Award, Analytical Chemistry Spectrochemical Analysis Award, the Pittsburgh Analytical Chemistry Award, and the ACS National Award for Creative Invention. He is a member of the National Academy of Engineering, the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Institute for Medical and Biological Engineering, and a Fellow of the National Academy of Inventors. He received a BS in Chemistry from the University of Michigan and a PhD in Chemical Biology from SUNY at Stony Brook, and did postdoctoral studies at MIT.